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Abstract
The chronic myeloproliferative disorders are clonal hematopoietic stem cell disorders of unknown
etiology. In one of these (chronic myeloid leukemia), there is an associated pathognomonic
chromosomal abnormality known as the Philadelphia chromosome. This leads to constitutive
tyrosine kinase activity which is responsible for the disease and is used as a target for effective
therapy. This review concentrates on the search in the other conditions (polycythemia vera,
essential thrombocythemia and idiopathic mylofibrosis) for a similar biological marker with
therapeutic potential. There is no obvious chromosomal marker in these conditions and yet
evidence of clonality can be obtained in females by the use of X-inactivation patterns. PRV-1mRNA
over expression, raised vitamin B12 levels and raised neutrophil alkaline phosphatase scores are
evidence that cells in these conditions have received excessive signals for proliferation, maturation
and reduced apoptosis. The ability of erythroid colonies to grow spontaneously without added
external erythropoietin in some cases, provided a useful marker and a clue to this abnormal
signaling. In the past year several important discoveries have been made which go a long way in
elucidating the involved pathways. The recently discovered JAK2 V617F mutation which occurs in
the majority of cases of polycythemia vera and in about half of the cases with the two other
conditions, enables constitutive tyrosine kinase activity without the need for ligand binding to
hematopoietic receptors. This mutation has become the biological marker for these conditions and
has spurred the development of a specific therapy to neutralize its effects. The realization that
inherited mutations in the thrombopoietin receptor (c-Mpl) can cause a phenotype of
thrombocytosis such as in Mpl Baltimore (K39N) and in a Japanese family with S505A, has
prompted the search for acquired mutations in this receptor in chronic myeloproliferative disease.
Recently, two mutations have been found; W515L and W515K. These mutations have been evident
in patients with essential thrombocythemia and idiopathic myelofibrosis but not in polycythemia
vera. They presumably act by causing constitutional, activating conformational changes in the
receptor. The discovery of JAK2 and Mpl mutations is leading to rapid advancements in
understanding the pathophysiology and in the treatment of these diseases.
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Introduction
The concept of the myeloproliferative disorders was intro-
duced by Dameshek more than 50 years ago [1]. He sug-
gested then that these conditions were "closely
interrelated" and due to a proliferative activity of the bone
marrow by an undiscovered stimulus. In the case of one
these conditions, chronic myeloid leukemia (CML), the
stimulus became evident with the discovery of the Phila-
delphia chromosome and the translocation which results
in the BCR/ABL fusion gene. This abnormal gene codes for
a protein which has constitutive tyrosine kinase activity in
cellular signaling pathways controlling proliferation and
differentiation. The marrow is therefore chronically stim-
ulated not due to excess external signals as suggested by
Dameshek, but due to a fault in the signaling pathway
itself caused by the translocation. As a result of these dis-
coveries CML is now considered a separate entity and has
a specific and effective therapy.
The other three main chronic myeloproliferative diseases
are today recognized as Polycythemia Vera (PV), Essential
Thrombocythemia (ET) and Myelofibrosis (IMF). These
conditions are clonal disorders of hematopoietic progen-
itor cells which have the capacity to differentiate into
excess numbers of mature cells. In PV the emphasis is on
an excess production of red cells leading to a raised hema-
tocrit and possible thrombotic complications if left
untreated. Raised neutrophil and platelet counts may also
be evident. In ET the emphasis is very much on an exces-
sive production of platelets which may be markedly raised
and result in a bleeding or a thrombotic tendency. The
neutrophil count may also be raised but the hematocrit is
normal. These two conditions are associated with a long
median survival if patients do not suffer thrombotic or
hemostatic complications. The third disease in this cate-
gory, IMF, has however, a worse prognosis with a median
survival that may be only 3.5 to 5 years [2]. In this condi-
tion there is fibrosis within the bone marrow leading to
extramedullary hematopoiesis, enlargement of the spleen
and bone marrow failure. Fibrosis is a secondary phenom-
enon due to release of cytokines from neoplastic meg-
akaryocytes. This condition may occur in a patient with
previous PV or ET, or may occur without any evident ante-
cedent disease.
The search for biological markers in chronic 
myeloproliferative disease
Molecular markers for chronic myeloproliferative dis-
eases, such as the Philadelphia chromosome in CML, have
long been searched for, but little progress has been made
until recently. While visible chromosomal abnormalities
can be detected in about 33% of patients with PV[3] no
single abnormality is pathognomonic for PV, ET, or IMF
as the Philadelphia chromosome is for CML. Recurrent
chromosomal abnormalities have however been docu-
mented. A 20q deletion occurs in 10% of patients with PV
and IMF, but the most common abnormality is the find-
ing of a loss of heterozygosity of 9p in up to 33% of PV
patients [4]. In ET detection of karyotype abnormalities is
infrequent [3].
The lack of a chromosomal marker in PV and ET in partic-
ular leads to diagnostic difficulties. The diagnosis of both
of these disorders has largely been by exclusion of condi-
tions known to cause an elevated hematocrit or platelet
count. A search has therefore been underway for many
years for positive pathological features which could help
in establishing the diagnosis. For many years clinical cri-
teria was supplemented with the result of testing for
clonal or abnormal hematopoiesis. More recently, molec-
ular markers have been identified that are proving to be
useful in the diagnosis of these diseases.
Clonal hematopoiesis
The first useful marker for chronic myeloproliferative dis-
ease was the detection of clonal hematopoiesis. Initially
the use of X-inactivation patterns in females established
clonality in cell lineages such as granulocytes [5-7]. How-
ever, these assays were technically demanding and not
widely available.
Endogenous erythroid colonies
The measurement of endogenous colonies has been an
important marker for diagnosing PV. In normal individu-
als erythroid colonies will only grow in culture media sup-
plemented with erythropoietin (EPO). A characteristic
feature of PV is the ability for erythroid progenitor cells
obtained from blood or bone marrow to grow in semi-
solid, serum-containing cultures in the absence of EPO
[8]. This "spontaneous" growth of erythroid colonies is
known as endogenous erythroid colony (EEC) formation
and is also observed in some cases of ET and IMF, but not
in normal subjects. The formation of EEC was thought at
first to be due to hypersensitivity of these cells to minute
quantities of EPO in the culture media [9] as well as other
growth factors such as IL-3, stem cell factor, GM-CSF,
thrombopoietin (TPO) and insulin like growth factor
(IGF-1) [10-13]. This augmented response of erythroid
progenitors to growth factors suggested that these cells
had an abnormality in the EPO signaling mechanism that
controlled the processes of erythroid proliferation, matu-
ration and apoptosis. The situation is similar in CML
where the BCR/ABL protein conveys constitutive tyrosine
kinase activity. Later, it became clear, however, that
growth of these colonies was truly independent of EPO
since it was not blocked by anti-EPO neutralizing anti-
bodies [14].
Although the detection of EEC is a laborious procedure,
requires adequate standardization and is not freely avail-Journal of Translational Medicine 2006, 4:41 http://www.translational-medicine.com/content/4/1/41
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able to many centers, it is accepted as a major diagnostic
criteria for PV according to WHO and European recom-
mendations [15].
EPO levels are typically low in PV, but this finding is only
accepted as a minor criteria according to these recommen-
dations.
Spontaneous megakaryocytic colonies can also be grown
without thrombopoietin in chronic myeloproliferative
disease. Although first described as a useful test to dis-
criminate between ET and reactive thrombocytosis or nor-
mal subjects [16], spontaneous colonies can also be seen
in PV and IMF [17,18].
PRV-1 mRNA over-expression and CD177
The first useful molecular marker of chronic myeloprolif-
erative diseases was the measurement of granulocyte lev-
els of PRV-1 mRNA. [19] Several studies have suggested
that the granulocyte over-production of PRV-1 mRNA was
a marker of clonal hematopoieisis in PV [20-22]. These
studies have found that approximately 69 to 91% of PV
patients have elevated granulocyte PRV-1 mRNA levels.
Others have found increased expression in every patient
with PV [23]. This variability may be due differences in
sample handling. The time that elapses prior to processing
of blood samples after collection may be a crucial factor
[24]. The use of whole blood rather than purified granu-
locytes and the choice of the housekeeping gene used to
compare gene expression may also be important [25].
Granulocyte PRV-1 mRNA levels have also been found to
be elevated in approximately 17 to 67% of patients with
ET [20-22]and 46% with IMF [20].
Unfortunately elevations in granulocyte PRV-1 mRNA lev-
els are not as specific for the chronic myeloproliferative
diseases as initially believed. Levels of granulocyte PRV-1
mRNA can be transiently elevated in healthy subjects.
PRV-1 is a member of the uPAR/Ly6/CD59 family of
receptors. The gene PRV-1, and the gene encoding a neu-
trophil alloantigen, NB1, are alleles of a single gene,
CD177, in chromosome band 19q13.31 [26]. CD177
glycoprotein can be recognized in neutrophil plasma
membranes by immunofluorescence on analysis with
monoclonal antibodies. In normal individuals only about
50% of neutrophils express CD177. The numbers are
higher in women and increase in pregnancy, with infec-
tion and after G-CSF administration [27]. Granulocyte
PRV-1 mRNA levels are also increased in healthy subjects
given G-CSF or with infection. Neutrophil CD177 antigen
density per cell is also increased in patients with PV [28],
however, flow cytometry measurement of neutrophil
CD177 expression cannot be used in the diagnosis of PV
since the numbers of CD177 positive neutrophils is not
consistently elevated compared to controls [29]. The
explanation for the lack of association in PV patients
between CD177 expression at the mRNA level and cell
surface CD177 protein expression is not apparent. It may
be due to a fault in processing or due to a release of the
protein into plasma. This is the case in other similar pro-
teins which have a GPI (glycosyl-phosphatidylinositol)
attachment [30].
It appears that the increased PRV-1 mRNA levels are a sec-
ondary phenomenon to myeloproliferation rather than
the cause of the abnormal hematopoeisis. Other useful
biomarkers such as high plasma vitamin B12 levels and
raised neutrophil alkaline phosphatase scores are also sec-
ondary events
JAK2 V617F
A specific mutation in the Janus kinase, JAK2, has been
identified in the majority of patients with PV and in many
patients with ET and IMF. The presence of this somatic
mutation in myeloid cells has proven to be more specific
for myeloproliferative diseases than elevated PRV-1
mRNA levels and its assessment has now become a stand-
ard molecular assay for the diagnosis of PV.
The Janus Kinases
The receptors for EPO, G-CSF, GM-CSF, TPO and some
interleukins are termed type I cytokine receptors. These
are characterized by a lack of a cytoplasmic tyrosine kinase
domain and instead use an intracellular JAK-STAT path-
way to initiate signaling [31]. The STAT pathway refers to
Signal Transducers and Activators of Transcription which
are responsible for directly influencing gene expression.
JAK refers to the Janus Kinases, named after the Greek-
Roman god of gates and passageways. Initially one kinase
involved in this system was identified and this was skepti-
cally nicknamed "just another kinase". Three more mem-
bers of this family have been found and they are now
recognized to be crucially important in growth factor and
cytokine signaling. JAK-2 was the third Janus kinase dis-
covered and it is involved in haemopoietic receptor sign-
aling for EPO, G-CSF, GM-CSF and TPO.
JAKs bind to juxtamembrane cytoplasmic regions of type
I cytokine receptors by their FERM (Four-point-one, Ezrin,
Radixin, Moesin) domain. In the unliganded state, the
receptor exists as a dimer separated by 73 Å. After binding
with an activating ligand, a conformational change occurs
resulting in the reduction of the separation of the two
strands to 39 Å [32]. This allows close apposition of two
bound JAK-2 molecules and their mutual activation by
cross – phosphorylation. Once activated JAK-2 exerts
kinase action via its JH1 domain initially on the receptor
itself providing docking sites for STATs and later for other
signaling and regulatory elements.Journal of Translational Medicine 2006, 4:41 http://www.translational-medicine.com/content/4/1/41
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In addition to the FERM domain, JAK2 has two other
domains JH1 and JH2. The JH1 domain is situated near
the carboxyl terminal of the protein. Proximal to this is a
JH2 domain which has no kinase activity, but normally
prevents the kinase activity of JH1 by interacting with its
activation loop. When ligand binds, the resulting confor-
mational changes in the receptor and in the bound JAK-2
cause a separation of the JH2 inhibitory domain from
JH1. This leads to the expression of kinase activity (Figure
1) [33,34].
The domains of JAK2 illustrating binding to the receptor and changes consequent to receptor binding and mutation in the JH2  domain Figure 1
The domains of JAK2 illustrating binding to the receptor and changes consequent to receptor binding and 
mutation in the JH2 domain. The V617F mutation of the JH2 domain of JAK2 results in constitutive kinase activation. Panel 
A: When no ligand in bound to the EPO, TPO, G-CSF or GM-CSF receptors, the kinase activity of the JH1 domain is inhibited 
by the JH2 domain and JAK2 is inactive. Panel B: When EPO binding to it receptor, the two strands of the receptor come 
closer together, JAK2 changes conformation, the JH1 kinase activity in no longer inhibited by JH2. Panel C: The JAK2 V617F 
mutation prevents JH2 from inhibiting JH1 and the kinase is active even when no ligand is bound by the receptor.Journal of Translational Medicine 2006, 4:41 http://www.translational-medicine.com/content/4/1/41
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The importance of the JAK2 V617F mutation
The critical role of JAK2 in signal transduction by hemat-
opoietic growth factor and cytokine receptors suggested
that JAK2 might have abnormal tyrosine kinase activity in
chronic myeloproliferative disease. In Drosophila a muta-
tion in the JH2 domain causes a leukemia like picture due
to hyper activation of the JAK-STAT pathways [35]. In the
spring of 2005, almost simultaneously, five reports
appeared describing a mutation in the gene coding for
JAK2 also in this pseudo kinase JH2 domain, in patients
with chronic myeloproliferative diseases [36-40]. This was
a G to T mutation at nucleotide 1849, which leads to phe-
nylalanine being substituted for valine at codon 617
(V617F). This mutation leads to a lack of inhibition of the
JH1 domain and constitutive JAK2 kinase activity without
the coupling of ligands to hemopoietic receptors.
The mutation occurs mainly in PV with a frequency of
between 76% and 97% depending upon the method of
detection used and the accuracy in the diagnosis of PV. It
is less common in patients with ET (29–57%) and IMF
(50%). Most patients have a heterozygous mutation, but
in 30% the mutation is homozygous due to mitotic
recombination corresponding to LOH and more
advanced disease [4,38,39,41]. Analysis of BFU-e cells
after cell culture however, has shown homozygous muta-
tions in all cases of PV, but not in ET unless they devel-
oped a PV phenotype [42]. This mutation is found only
occasionally in other hematological diseases: 3% in
patients with chronic myelomonocytic leukemia, 5% in
other myelodysplastic syndromes, 2 out of 8 patients with
systemic mastocytosis, 1 out of 6 with chronic neu-
trophilic leukemia and none out of 11 patients with the
hypereosinophilic syndrome [69]. It has also been found
in 6 out of 9 patients with refractory anemia with ringed
sideroblasts and thrombocytosis [43].
JAK2 V617 very likely has an important role in the patho-
biology of PV, since it gives cells with the mutation a pro-
liferative advantage. In vitro studies have found that cells
transfected with JAK2 V617 had a proliferation and sur-
vival advantage over wild type JAK2 transfected cells. The
JAK2 V617F transfected cell were more sensitive to stimu-
latory signals [44]. Cells transfected with JAK2 V617F were
also able to activate STAT mediated transcription in the
absence of erythropoietin, but cells transfected with wild-
type JAK2 did not [37]. Mice transplanted with bone mar-
row cells infected with murine JAK2  V617F developed
erythrocytosis four weeks after transplant but not mice
transplanted with cells transfected with murine wild-type
JAK2 [37].
In ET, patients with JAK2  V617F have a significantly
higher Hb level than without the mutation [45-47], sug-
gesting that these patients are more similar to PV. The
detection of this mutation by PCR in ET which can detect
2–4% of mutated cells, is more sensitive as a test for clon-
ality than X-chromosome inactivation patterns which
require at least 26% mutated cells. There are, however,
cases of ET who have monoclonal hematopoiesis accord-
ing to X-chromosome inactivation patterns but are nega-
tive for the JAK2 mutation [48], suggesting that in these
another mutation may be present. This may also be the
case in those patients with true PV who have EEC and
monoclonal hematopioesis but who do not have the JAK2
mutation.
Many of the markers previously useful in the diagnosis of
PV and ET may be due to a downstream effect of JAK2 acti-
vation. The myeloproliferation that results from constitu-
tive JAK2 activation could result in increased neutrophil
alkaline phosphatase scores, increased levels of vitamin
B12  (due to increased transcobalamin I) and CD177
mRNA overexpression. Interestingly, CD177  mRNA is
also overexpressed by neutrophils from healthy subjects
given G-CSF [28]. Since G-CSF stimulates neutrophils by
binding to the G-CSF receptor and activating JAK2, this
provides further evidence that JAK2 overactivation is
likely responsible for the overexpression of CD177 mRNA
in patients with PV.
The fact that JAK2 constitutive activation due to the V617F
mutation occurs in PV, ET and IMF suggests that those
with this mutation are part of a common disease with dif-
ferent expression due to other factors such as disease dura-
tion. It is also possible that the different phenotypes are
due to additional mutations influencing for instance meg-
akaryocytes and platelet production. This has now
become apparent with the discovery of c-Mpl mutations
in some cases (see later).
Using very sensitive techniques the JAK2 V617F has been
detected in up to 10% of healthy donors with normal
blood counts [49]. This suggests that the mutation may
occur as an early event in the development of the disease
or other factors are required for disease development. This
is seen in CML where BCR/ABL expression can occur in
normal individuals using sensitive techniques [50,51].
BCR/ABL specific T cells have also been found in healthy
individuals [52] which suggests an immune mechanism
for control of the disease.
Mutations in Cytokine receptors
The possibility that an acquired mutation in a cytokine
receptor may be responsible for myeloproliferative dis-
ease has been suspected but until now none have been
found. Inherited mutations with a proliferative pheno-
type are however occasionally seen. With the erythropoie-
tin receptor (EpoR) for example, a truncated receptor with
loss of the cytoplasmic carboxyl terminal leads to familialJournal of Translational Medicine 2006, 4:41 http://www.translational-medicine.com/content/4/1/41
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polycythemia [14]. In this mutation there is loss of the
docking site for SHP1 which normally would dephospho-
rylate JAK2. Prolonged phosphorylation of JAK2/STAT5
and prolonged erythropoietin "on" signals lead to a high
hematocrit.
Mutations have been found in the G-CSF (G-CSFR) recep-
tor in some patients with severe congenital neutropenia
[53]. These initially have germline ELA-2 mutations which
cause neutrophil elastase deficiency and then develop a
secondary somatic mutation in the G-CSFR. This occurs in
the terminal cytoplasmic region responsible for the bind-
ing of SHP-1 and SOCS (suppression of cytokine signal-
ing) proteins leading to a hyperproliferative response
[54]. Many of these patients go on to develop acute mye-
loid leukemia.
The thrombopoietin receptor (c-Mpl)
Abnormalities of the thrombopoietin receptor known as
c-Mpl have been suspected of being involved in myelo-
proliferative diseases. In fact, c-Mpl was initially identified
as a proto-oncogene when its transmembranous and
intracellular domains were transduced into the envelope
of the myeloproliferative leukemia virus (MPLV) [55]. In
mice this virus causes a generalized myeloproliferative
polycythemic-like disorder with granulocytosis, thrombo-
cytosis and erythroblastosis [56]. This proliferation might
be due to loss of the extracellular domain which is
thought to exert an inhibitory effect. Truncation of this
area of c-Mpl causes TPO independent growth [57]. TPO
might exert its influence by leading to a relief of this block.
The expression of c-Mpl has been found to be reduced in
ET [58], PV and IMF [59]. This is related to incomplete c-
Mpl glycosylation rather than c-Mpl gene disruption or
transcriptional repression [60]. The expression of c-Mpl is,
however, also reduced in reactive thrombocytosis [61]
and in hereditary thrombocytosis caused by a TPO gene
mutation [62], showing that these findings are not spe-
cific for myeloproliferative disease.
Inherited mutations in c-Mpl
The recent discovery of two inherited mutations in c-Mpl
has fueled the search for acquired mutations in these dis-
orders. The first inherited mutation discovered was in a
Japanese family known to have "Familial" Essential
Thrombocythemia inherited in an autosomal dominant
manner. Here there is an amino acid change from serine
to asparagine in position 505 in the receptor (S505A),
resulting from a heterozygous G to A nucleotide substitu-
tion at position 1073 in exon 10 of c-MPL [63]. This muta-
tion occurs in the transmembranous portion of the
receptor and leads to constitutive activity of the receptor.
The second c-Mpl mutation found was Mpl Baltimore,
K39N [64], which is a polymorphism near the terminal
portion of the extra-cellular portion of the receptor (Fig-
ure 2). This results from a single base change guanosine to
thymidine at nucleotide 1238 in exon 2 and is found
exclusively in African Americans with a gene frequency of
7%. Heterozygotes have elevated platelet counts as com-
pared to controls and homozygotes have even higher
counts, in excess of 800 × 109/L.
The reason why these c-Mpl polymorphisms should cause
thrombocytosis is not entirely clear. They could allow the
receptor to assume an active configuration involving the
closer proximity of the two strands of the receptor dimer
and consequent JAK2 activation.
Acquired 515 mutations in c-Mpl
Recently it was suggested that abnormalities within a 5-
amino acid amphipathic motif (RWQFP in humans)
which is a juxtamembranal domain of the c-Mpl receptor,
leads to constitutive activation [65]. This area, which
extends from 514 to 518, is thought to prevent the two
strands of the c-Mpl dimer from approximating when lig-
and is not bound to the receptor (Figure 2). Two acquired
mutations have now been found at position 515 within
this motif, W515L [66] and W515K [67]. These reports
present the first evidence of a somatic mutation in a
cytokine receptor in chronic myeloproliferative diseases.
Polymorphism and mutations of the thrombopoietin recep- tor, c-Mpl Figure 2
Polymorphism and mutations of the thrombopoietin 
receptor, c-Mpl. Two polypmorphisms, c-Mpl K39N and 
S505A, lead to constitutive activity of c-Mpl and thrombocy-
tosis. Somatic mutations in the juxtamembranal domain of c-
Mpl also lead to constitutive activity and have been found in 
patients with ET and IMF.Journal of Translational Medicine 2006, 4:41 http://www.translational-medicine.com/content/4/1/41
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In 1182 patients '515' mutations were found in 20 [67].
Amongst the ET patients mutations were found in 1% and
amongst the IMF patients they were found in 4–5%. The
mutation was seen in 6 patients who were also JAK2
V617F heterozygous. It was not clear whether the JAK2
and c-Mpl mutations were in two separate clones or repre-
sent two mutations in the same clone. Two cases had a
mixed clonal state with both '515' mutations. The 515
mutations were not seen in PV suggesting in this disease
JAK2 V617F is prominent and is related to the phenotype
of red cell production. In contrast, c-Mpl mutations affect
megakaryocytes and lead to IMF and ET. The MPL515
mutations that have been detected thus far described are
infrequent, but it is expected that further c-Mpl mutations
will be discovered.
Conclusion
The identification of specific molecular mutations in
patients with chronic myeloproliferative disease has been
a significant clinical advancement. There is no doubt, that
the discovery of the JAK2 V617F mutation represents a
major advance in understanding the pathophysiology of
these disorders. It is an aid to diagnosis in some cases and
will no doubt lead to the development of specific therapy
in the future.
The identification of granulocyte JAK2 V617F is highly
specific for the diagnosis of PV and has rapidly replaced
other biochemical, cellular, and molecular diagnostic
assays. The presence of JAK2 V617F is also useful in eval-
uating patients with elevated platelet counts who are sus-
pected of having ET, although only approximately half of
all ET patients have JAK2V617F. Many clinical investiga-
tors are evaluating c-Mpl for mutations and polymor-
phisms in these ET patients with and without JAK2
mutations. Some ET patients will have c-Mpl mutations,
but the exact role of c-Mpl mutations in ET is not yet cer-
tain. ET is certainly a heterogeneous disease. It needs to be
separated from IMF and prodromal IMF by careful histo-
logical analysis of bone marrow biopsy specimens [68]
and from latent PV. The importance of the polyclonal ver-
sus the monoclonal forms of the disease need to be ascer-
tained. It is hoped that molecular markers will help in this
regard.
The identification of an activating mutation in JAK2 as a
cause of chronic myeloproliferative disease could have
important clinical implications. The development of spe-
cific inhibitors of the BCR/ABL kinase found in patients
with CML has had a remarkable clinical impact. They are
highly effective and have little toxicity. Specific inhibitors
of the abnormal JAK2 kinase are not yet available, but will
likely be tested and available in the near future. Since the
therapeutic modalities available to treat chronic myelo-
proliferative diseases are limited to phlebotomy, platelet
inhibitors, cytotoxic drugs and in some cases allogeneic
stem cell transplantation, the availability of an effective
and specific molecular therapy would be an enormous
advance.
While mutations in JAK2 may not be the molecular defect
that initiates PV, ET or IMF, the discovery of this molecu-
lar marker has made the diagnosis of PV and ET simpler,
faster and more precise. The more precise diagnosis and
classification of these patients will surely lead to more
rapid advances of clinical investigations aimed at further
defining the pathophysiology and more effective treat-
ment of these diseases.
Dameshek showed outstanding foresight in recognizing
and grouping together the chronic myeloproliferative dis-
eases. This has lead to developments in our understanding
of their common pathophysiological mechanisms and the
peculiar molecular events in each disease category result-
ing in different phenotypes. These are exciting times with
new discoveries coming at a tremendous pace. All of this
will no doubt eventually lead to the development of spe-
cific therapy and improved care for these patients.
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